Prothena Co. plc (NASDAQ:PRTA) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Prothena Co. plc (NASDAQ:PRTA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $55.00.

A number of brokerages have commented on PRTA. Cantor Fitzgerald restated an "overweight" rating on shares of Prothena in a research report on Friday, February 21st. HC Wainwright restated a "buy" rating and issued a $48.00 price objective on shares of Prothena in a research report on Friday, February 21st. StockNews.com raised Prothena from a "sell" rating to a "hold" rating in a research note on Monday, February 24th. Chardan Capital restated a "buy" rating and issued a $40.00 price target on shares of Prothena in a research note on Friday, February 21st. Finally, Royal Bank of Canada cut their price objective on Prothena from $24.00 to $20.00 and set a "sector perform" rating for the company in a research report on Friday, February 21st.

Prothena Stock Down 2.2 %

PRTA traded down $0.21 during trading on Friday, hitting $9.38. 8,174 shares of the stock were exchanged, compared to its average volume of 493,839. The firm has a market capitalization of $504.74 million, a P/E ratio of -4.07 and a beta of 0.07. Prothena has a 1-year low of $9.30 and a 1-year high of $25.42. The stock has a fifty day moving average price of $13.18 and a two-hundred day moving average price of $14.58.

Prothena (NASDAQ:PRTA - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.06). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The business had revenue of $2.12 million during the quarter, compared to analysts' expectations of $7.53 million. Analysts predict that Prothena will post -4.04 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC grew its holdings in shares of Prothena by 19.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock worth $71,000 after buying an additional 833 shares in the last quarter. GAMMA Investing LLC grew its stake in Prothena by 4,626.0% in the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company's stock worth $74,000 after acquiring an additional 5,875 shares during the period. Headlands Technologies LLC grew its stake in Prothena by 196.5% in the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company's stock worth $102,000 after acquiring an additional 4,858 shares during the period. Teacher Retirement System of Texas acquired a new stake in shares of Prothena during the fourth quarter worth $145,000. Finally, Purkiss Capital Advisors LLC acquired a new stake in shares of Prothena during the fourth quarter worth $149,000. Institutional investors and hedge funds own 97.08% of the company's stock.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.